Abstract:Abstract PROTACs are molecules that combine a target-binding warhead with an E3 ligase-recruiting moiety; by drawing the target protein into a ternary complex with the E3 ligase, PROTACs induce target protein degradation. While PROTACs hold exciting potential as chemical probes and as therapeutic agents, development of a PROTAC typically requires synthesis of numerous analogs to thoroughly explore variations on the chemical linker; without extensive trial and error, it is unclear how to link the two protein-recruiting moieties to promote formation of a productive ternary complex. Here, we describe a structure-based computational method for evaluating suitability of a given linker for ternary complex formation. Our method uses Rosetta to dock the protein components, then builds the PROTAC from its component fragments into each binding mode; complete models of the ternary complex are then refined. We apply this approach to retrospectively evaluate multiple PROTACs from the literature, spanning diverse target proteins. We find that modeling ternary complex formation is sufficient to explain both activity and selectivity reported for these PROTACs, implying that other cellular factors are not key determinants of activity in these cases. We further find that interpreting PROTAC activity is best approached using an ensemble of structures of the ternary complex rather than a single static conformation, and that members of a structurally-conserved protein family can be recruited by the same PROTAC through vastly different binding modes. To encourage adoption of these methods and promote further analyses, we disseminate both the computational methods and the models of ternary complexes. Significance Statement Recent years have brought a flood of interest in developing compounds that selectively degrade protein targets in cells, as exemplified by PROTACs. Fully realizing the promise of PROTACs to transform chemical biology by delivering degraders of diverse and undruggable protein targets has been impeded, however, by the fact that designing a suitable chemical linker between the functional moieties requires extensive trial and error. Here, we describe a structure-based computational method to predict PROTAC activity. We envision that this approach will allow design and optimization of PROTACs for efficient target degradation, selection of E3 ligases best suited for pairing with a given target protein, and understanding the basis by which PROTACs can exhibit different target selectivity than their component warheads.

Hand construction of quadrifilar wire electrodes for electromyography

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Predicting Degradation Potential of Protein Targeting Chimeras

Modeling PROTAC Degradation Activity with Machine Learning

Interpretable PROTAC degradation prediction with structure-informed deep ternary attention framework

An overview of PROTACs: a promising drug discovery paradigm

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Importance of Three-Body Problems and Protein-Protein Interactions in Proteolysis-Targeting Chimera Modeling: Insights from Molecular Dynamics Simulations

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

TRL-PROTAC: A pre-trained generator of PROTACs targeting specific proteins optimized by reinforcement learning

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]

Precise Modulation of Protein Degradation by Smart PROTACs

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

A close-up shot of protein-protein docking, from experiment to theory and reverse with the PROTAC performers

Recent advances of PROTACs technology in neurodegenerative diseases

De novo PROTAC design using graph-based deep generative models

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Rationalizing PROTAC-mediated ternary complex formation using Rosetta

Targeted protein degradation: expanding the toolbox